Utilization of CRISPR/Cas9 gene editing in cellular therapies for lymphoid malignancies.

We describe current and future therapeutic application of CRISPR/Cas9 technology with the focus on the production and applications of engineered hematopoietic and immune cells against lymphoid malignancies. Furthermore, we provide an overview of the possible challenges and optimization of CRISPR/Cas9 system for ex- and in vivo applications within recent years.
PMID: 32687855 [PubMed - as supplied by publisher]

Source: Immunology Letters - July 16, 2020 Category: Allergy & Immunology Authors: Mehravar M, Roshandel E, Salimi M, Chegeni R, Gholizadeh M, Mohammadi MH, Hajifathali A Tags: Immunol Lett Source Type: research